You should consider shares of Sempra Energy (NYSE:SRE) and Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) if you are looking for a great stocks to invest in. Starting with the SRE shares, which traded at $158.97 at the close of the recent session, dropping -1.30%. On Tuesday, the company’s shares shed -$2.09 from its value which represented in intraday trading. The stock is now 4.94% higher in year-to-date (YTD) trading. SRE’s intraday high was $161.66 while its lowest price touched $158.78. The stock’s 52-week high price is $161.87, which means the current price is at -1.79%. In terms of trading activity, the daily trading volume fell to 1422049 against 200-day average trading volume of 1,454,242 shares.
What are analyst forecasts for Sempra Energy (NYSE:SRE)?
At a consensus rating of 3.80, SRE is trending as a streaking Moderate Buy, as it has been the case a month ago when 9 analysts called it a Moderate Buy. Two months ago, 9 analysts recommended, on average, that SRE stock is a Moderate Buy. The Utilities company’s shares’ overall bearish trend saw it close higher on Tuesday compared to its opening price of $160.68 on the day.
Forecasts for Sempra Energy (NYSE:SRE) give the stock a fair value for the growth of 4.81% from its last price. The 12-month price forecast for the stock by analysts puts the stock’s mean price target at $167.00, which means the price per share could rise by nearly $8.03. The price range target is between a low of $151.00 and a high of $186.00. The stock would need to gain by about $14.53 to hit the estimated high or 0.71% from its 12-month low.
The consensus among 15 analysts is that it is a good time for one to Overweight in the Sempra Energy. 9 analysts rate SRE as a Buy, with 0 of 15 analysts rate it as a Sell. 0 have valued the stock as Overweight and 5 have recommended that investors Hold.
Sempra Energy (NYSE:SRE) Upgrades and Downgrades
In terms of rating changes, Barclays on August 13, 2019, Initiated Sempra Energy (SRE) at Equal Weight. They believe the stock could reach $142 in the near term. Analysts at BofA/Merrill have assigned a Neutral rating for the stock in their research note on June 27, 2019 with an estimated price target of $142. Moreover, KeyBanc Capital Markets analysts issued a rating of Overweight for the stock on June 05, 2019, giving it a price target of $151 for the next 12 months. On October 11, 2018, the stock earned a Buy rating due to an analyst call from BofA/Merrill, while analysts from Wells Fargo on August 20, 2018 suggested that the stock is Outperform.
Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) adds $0.04 on Tuesday
The CPRX stock has risen 13.33% year-to-date and is currently trading at $4.25, which is -44.59% below its 52-week high. The company shares gained 0.95% on the day and have risen nearly 95.85% off a low hit. At current levels, Catalyst Pharmaceuticals Inc. has a valuation of about $72.70M. As of 02/04/20, this stock has fallen -0.70% during the week and closed at $4.21 in the previous session. However, recent Catalyst Pharmaceuticals Inc. stock performance shows that CPRX shares are 13.94% up over the last month, and -11.64% down for the last three months.
Earnings per share (EPS) estimates for the current quarter are -$0.11, with the trailing 12-month share earnings at $0.08. The ratio is expected to be up by 203.00% for the current year 2019 and 38.20% for next year. But will the CPRX stock surprise in the current quarter results, where the $0.13 actual EPS reported on 9/29/2019 surprised by 18.20% or was higher by $0.02 from the estimated $0.11.
Sales Growth to climb 43.40% for the year
How well will Catalyst Pharmaceuticals Inc. perform as a business over the current quarter, year and next 5-year period? Compared to the year-ago quarter, analysts forecast the company to bring in between $27.82M and $31M in current quarter sales. The consensus estimated for the current quarter is $29.4M from sales. Forecasts for this fiscal year are between $100M and $103.2M and the consensus estimate for sales is at $101.58M. CPRX has its next quarter sales estimates at between $28.31M and $32.88M, with the quarter-over-quarter growth estimates at 149.50% and the annual growth forecast for the year at 43.40%.
Who owns shares in Catalyst Pharmaceuticals Inc. (CPRX)?
Let’s briefly focus on the share ownership of the Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) stock, where we find that 43.18% of shares are held by institutions. Consonance Capital Management LP tops the list of institutional owners as it is holding 17.88 million shares or 17.35% of shares outstanding. Blackrock Inc. and Vanguard Group, Inc. (The) held 8.26 million and 4.88 million representing 8.01% and 4.74% respectively at the close of the last trading session. As of Sep 29, 2019, State Street Corporation accounted for 3.63 million shares at over 19.26 million. This represented 3.52% of shares outstanding. Morgan Stanley held 2.64 million shares at over 14.02 million representing 2.56% of shares outstanding.
CPRX Insider Activity
Insider activity can also give a signal in terms of price direction. Looking at Catalyst Pharmaceuticals Inc. (CPRX), a total of 350000 shares have been sold by insiders over the last 6 months while 370000 shares were added in the same time span. On 12/05/2019, Chief Medical Officer by the name Ingenito Gary sold 150000.0 shares worth $723000.0 at the price of $4.82 per share. Filings also show that Ingenito Gary sold a total of 100000.0 shares on 11/27/2019 valued at $466000.0. Since the last insider activity, the company’s share price has dropped -9.19%.